{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-26-000063","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2026-08-06T11:23:01+00:00","discovered_at":"2026-08-06T11:25:00.361040+00:00","generated_at":"2026-08-06T11:25:13.759656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tarsus Q2 XDEMVY sales $173.9M (+69% YoY); raises FY guidance to $685-705M; acquires Alkeus","bullets":["XDEMVY net product sales $173.9M in Q2 2026, up >69% YoY; full-year guidance raised to $685-705M.","Net loss narrowed to $18.6M ($0.43 loss per share) from $20.3M ($0.48) in Q2 2025.","Cash, cash equivalents and marketable securities $449.7M as of June 30, 2026.","Announced agreement to acquire Alkeus Pharmaceuticals (Phase 3 Stargardt disease therapy) and $125M private placement.","Appointed Neera Clase as Interim Chief Commercial Officer; pipeline milestones on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-26-000063","json":"https://secwatch.observer/filing/0001819790-26-000063.json","markdown":"https://secwatch.observer/filing/0001819790-26-000063.md","text":"https://secwatch.observer/filing/0001819790-26-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/0001819790-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/tars-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:25:13.759656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}